Interpace Diagnostics Introduces New AccuCEA Insights for Diagnosing and Treating Pancreatic Cancer

LW Newsfeed
Interpace Diagnostics Group (NASDAQ: IDXG), a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management, reported today that the Company has launched a new version of their AccuCEA™ product called “Insights” for Gastroenterologists who focus on diagnosing and treating pancreatic cancer.

The new AccuCEA Insights service provides physicians for whom the Company has already provided first line testing, with additional information on how those results compare to those of other patients in the Company’s proprietary database of over 15,000 patients, thus reporting incremental and valuable information on the patient’s potential molecular profile and overall risk for developing pancreatic cancer. When the report is delivered to the ordering physician, they have an opportunity to speak with one of the Company’s expert molecular pathologists and discuss the potential benefits of conducting a full, molecular pathology review using PancraGen®, the Company’s fully integrated product that considers all the results from first line testing, imaging, cytology, and molecular testing and stratifies the patient in one of 4 risk categories. Read more . . .


Conversation